Study to Determine the Pharmacokinetics of Product 0405
Phase 3
Withdrawn
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Product 0405
- Registration Number
- NCT02176577
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Brief Summary
The purpose of this study is to evaluate the Pharmacokinetics of Product 0405 in the Treatment of Atopic Dermatitis in Adolescent Subjects.
- Detailed Description
Treament medication will be administered topically twice daily for 28 days.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Clinical diagnosis of Atopic Dermatitis
- Good health with the exception of Atopic Dermatitis
- Percent body surface area minimums
Exclusion Criteria
- Subject who are nursing, pregnant or planning a pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Product 0405 Product 0405 Topically Active Investigational Product 0405
- Primary Outcome Measures
Name Time Method Phamacokinetic sampling 28 days
- Secondary Outcome Measures
Name Time Method Laboratory tests, vital signs, adverse events and local skin safety signs 28 days